Global Non alcoholic Steatohepatitis Market Size By Type (Solid, Liquid), By Application (Oral, Parenteral), By Region, And Segment Forecasts, 2023 to 2032

lobal Non-Alcoholic Steatohepatitis (NASH) Market Report Description

The Global Non-Alcoholic Steatohepatitis (NASH) Market was valued at USD 4.6 billion in 2023 and is projected to reach USD 20.1 billion by 2031, growing at a CAGR of 20.1% during the forecast period from 2023 to 2031. The market is witnessing substantial growth due to the rising prevalence of obesity, type 2 diabetes, and sedentary lifestyles globally. Increased awareness and improved diagnostic capabilities are further fueling early detection and therapeutic intervention, leading to increased demand for NASH treatment solutions.

Drivers

Growing Obesity and Diabetes Rates

The rising incidence of metabolic syndrome components, including obesity and type 2 diabetes, is significantly contributing to the increasing prevalence of NASH worldwide. As these conditions are closely linked to the development of NASH, the demand for effective treatment options is on the rise.

Advancements in Diagnostic Tools

The development of non-invasive diagnostic methods such as imaging biomarkers and fibrosis scoring systems is enabling early and more accurate diagnosis, which is crucial for managing disease progression and improving patient outcomes.

R&D Investments and Pipeline Expansion

Pharmaceutical companies are investing heavily in research and development to innovate and commercialize novel therapies for NASH. Numerous drugs in various stages of clinical trials signal promising growth prospects.

Restraints

Lack of Approved Therapeutics

Despite a strong pipeline, the current absence of widely approved and effective therapeutic options limits treatment accessibility and market potential.

Complex Disease Pathophysiology

The multifactorial nature of NASH, involving hepatic fat accumulation, inflammation, and fibrosis, poses significant challenges to drug development and therapeutic standardization.

Opportunity

Emerging Markets Adoption

The expansion of healthcare infrastructure in emerging markets, along with rising awareness and screening programs, offers lucrative growth opportunities for market players.

Biomarker and Companion Diagnostic Development

Advancements in personalized medicine and the development of companion diagnostics present opportunities to improve treatment targeting and efficacy.

Market by System Type Insights

The pharmacological treatment segment, including PPAR agonists and FXR agonists, held the largest market share in 2023. Due to their ability to target key pathways involved in the progression of NASH, these drug classes are gaining significant traction. The demand is expected to surge as several late-stage pipeline candidates approach market entry.

Market by End-use Insights

Hospitals and specialty clinics dominated the market in 2023, accounting for over 60% of global revenue. These settings are pivotal in early diagnosis, management of comorbidities, and patient monitoring. The segment is expected to maintain its dominance, supported by increasing patient volume and multidisciplinary care models.

Market by Regional Insights

North America held the largest share of the global NASH market in 2023, driven by the high prevalence of risk factors, advanced healthcare infrastructure, and active clinical trial landscape. However, the Asia-Pacific region is projected to register the fastest growth, bolstered by improving healthcare access, rising obesity rates, and expanding pharmaceutical investments in countries like China and India.

Competitive Scenario

Key players in the Global NASH Market include Intercept Pharmaceuticals, Inc., Genfit SA, Gilead Sciences, Inc., Madrigal Pharmaceuticals, Inc., and Viking Therapeutics, Inc. These companies are focusing on expanding their product pipelines, conducting robust clinical trials, and forming strategic collaborations to gain regulatory approvals and broaden their market reach.

Key Developments:

In 2023, Madrigal Pharmaceuticals announced positive Phase III results for its resmetirom therapy, targeting liver fibrosis in NASH patients.

Gilead Sciences entered a partnership with Novo Nordisk in 2024 to develop combination therapies addressing metabolic dysfunction in NASH.

Intercept Pharmaceuticals resubmitted a new drug application (NDA) to the FDA for obeticholic acid in 2025, following successful long-term efficacy data.

Scope of Work – Global Non-Alcoholic Steatohepatitis (NASH) Market

Report Metric Details

Market Size (2023) USD 4.6 billion

Projected Market Size (2031) USD 20.1 billion

CAGR (2023–2031) 20.1%

Market Segments System Type (Pharmacological, Non-drug), End-use (Hospitals, Specialty Clinics)

Growth Drivers Increasing prevalence of obesity and diabetes, advancement in diagnostics, and pipeline expansion

Opportunities Emerging markets adoption, biomarker and companion diagnostic development

FAQs

What is the current market size of the Global Non-Alcoholic Steatohepatitis Market?

The market was valued at USD 4.6 billion in 2023.

What is the major growth driver of the Global Non-Alcoholic Steatohepatitis Market?

The key growth driver is the increasing prevalence of obesity and type 2 diabetes worldwide.

Which is the largest region during the forecast period in the Global Non-Alcoholic Steatohepatitis Market?

North America remains the largest region due to high diagnosis rates and robust healthcare infrastructure.

Which segment accounted for the largest market share in Global Non-Alcoholic Steatohepatitis Market?

The pharmacological t